Failure to achieve clinical response or remission · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in failure to achieve clinical response or remission compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in adverse events compared with placebo with anti‐TNF (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in withdrawal due to adverse events compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with active Crohn's disease
Antibiotic showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
1 finding from 1 review
Failure to achieve clinical response · Patients with active Crohn's disease
Antibiotic probably leads to lower failure to achieve clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review